JP2002510633A5 - - Google Patents

Download PDF

Info

Publication number
JP2002510633A5
JP2002510633A5 JP2000542009A JP2000542009A JP2002510633A5 JP 2002510633 A5 JP2002510633 A5 JP 2002510633A5 JP 2000542009 A JP2000542009 A JP 2000542009A JP 2000542009 A JP2000542009 A JP 2000542009A JP 2002510633 A5 JP2002510633 A5 JP 2002510633A5
Authority
JP
Japan
Prior art keywords
mammalian
compound
pharmaceutical composition
excipient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000542009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510633A (ja
JP4443043B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/007471 external-priority patent/WO1999051238A1/en
Publication of JP2002510633A publication Critical patent/JP2002510633A/ja
Publication of JP2002510633A5 publication Critical patent/JP2002510633A5/ja
Application granted granted Critical
Publication of JP4443043B2 publication Critical patent/JP4443043B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000542009A 1998-04-06 1999-04-05 半合成エクテイナシジン Expired - Fee Related JP4443043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8080298P 1998-04-06 1998-04-06
US60/080,802 1998-04-06
PCT/US1999/007471 WO1999051238A1 (en) 1998-04-06 1999-04-05 Semi-synthetic ecteinascidins

Publications (3)

Publication Number Publication Date
JP2002510633A JP2002510633A (ja) 2002-04-09
JP2002510633A5 true JP2002510633A5 (enExample) 2006-05-25
JP4443043B2 JP4443043B2 (ja) 2010-03-31

Family

ID=22159716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542009A Expired - Fee Related JP4443043B2 (ja) 1998-04-06 1999-04-05 半合成エクテイナシジン

Country Status (27)

Country Link
US (1) US6124293A (enExample)
EP (2) EP1876180A3 (enExample)
JP (1) JP4443043B2 (enExample)
KR (1) KR100603219B1 (enExample)
CN (1) CN1157189C (enExample)
AT (1) ATE370148T1 (enExample)
AU (1) AU758100B2 (enExample)
BG (1) BG65088B1 (enExample)
BR (1) BR9909488B1 (enExample)
CA (1) CA2327468C (enExample)
CY (1) CY1106988T1 (enExample)
CZ (1) CZ301083B6 (enExample)
DE (1) DE69936845T2 (enExample)
DK (1) DK1067933T3 (enExample)
ES (1) ES2292237T3 (enExample)
HU (1) HUP0104273A3 (enExample)
IL (2) IL138856A0 (enExample)
MX (1) MXPA00009840A (enExample)
NO (1) NO328147B1 (enExample)
NZ (1) NZ507350A (enExample)
PL (1) PL196809B1 (enExample)
PT (1) PT1067933E (enExample)
RU (1) RU2217432C2 (enExample)
SK (1) SK285669B6 (enExample)
TR (1) TR200002921T2 (enExample)
UA (1) UA59439C2 (enExample)
WO (1) WO1999051238A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1195514C (zh) * 1998-05-11 2005-04-06 法马马有限公司 海鞘素 743的代谢物
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1339713A2 (en) 2000-11-03 2003-09-03 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
HRP20090345T1 (en) * 2004-10-26 2009-08-31 Pharma Mar S.A. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN100355775C (zh) * 2006-01-20 2007-12-19 南方医科大学 一种海鞘多肽及其制备方法
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
KR102452022B1 (ko) 2010-11-12 2022-10-06 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
JP2019504061A (ja) * 2016-02-04 2019-02-14 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
US5440055A (en) * 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Similar Documents

Publication Publication Date Title
JP2002510633A5 (enExample)
WO2002020466B1 (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
MY118156A (en) Oral compositions of levosimendan.
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
MXPA04003532A (es) Pirimidinonas como receptor 1 de la hormona concentradora de melanina.
CA2284732A1 (en) Analogs of cocaine
EP1422217A3 (en) Aminocyclohexyl ether compounds and uses thereof
AU7031500A (en) Therapeutic quinazoline compounds
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
EP0709376A3 (en) Therapeutic compounds
EP1024145A3 (en) Novel azalides and methods of making same
EP1772142A3 (en) Organic compounds
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
JP2003522198A5 (enExample)
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
JP2002522501A5 (enExample)
CA2470484A1 (en) A combination comprising combretastatin and anticancer agents
EP2452684A3 (en) Micelles
EP0992509A3 (en) Novel macrolide derivatives
JP2002506864A5 (enExample)
PL342614A1 (en) Anticarcinogenic drugs
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat